Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-05-22
DOI
10.1186/s40425-019-0601-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chaperonin (HSP60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma
- (2017) İsmail Ağababaoğlu et al. MEDICINE
- Annexin A2 inhibition suppresses ovarian cancer progression via regulating β-catenin/EMT
- (2017) Yan Liu et al. ONCOLOGY REPORTS
- Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis
- (2017) Takahiro Tsujikawa et al. Cell Reports
- Current progress in immunotherapy for pancreatic cancer
- (2016) Kelly Foley et al. CANCER LETTERS
- Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer
- (2016) Agnieszka A. Rucki et al. CANCER RESEARCH
- Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
- (2016) Hong Jiang et al. NATURE MEDICINE
- Annexin A2 and its downstream IL-6 and HB-EGF as secretory biomarkers in the differential diagnosis of Her-2 negative breast cancer
- (2016) Praveenkumar Shetty et al. ANNALS OF CLINICAL BIOCHEMISTRY
- T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma
- (2015) Ingunn M. Stromnes et al. CANCER CELL
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
- (2015) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
- (2015) Kevin C. Soares et al. JOURNAL OF IMMUNOTHERAPY
- Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer
- (2015) Kelly Foley et al. Science Signaling
- TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner
- (2015) Kevin C. Soares et al. Oncotarget
- Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer
- (2015) Kelly Foley et al. Science Signaling
- Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
- (2015) R. Winograd et al. Cancer Immunology Research
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- A Listeria Vaccine and Depletion of T-Regulatory Cells Activate Immunity Against Early Stage Pancreatic Intraepithelial Neoplasms and Prolong Survival of Mice
- (2014) Bridget P. Keenan et al. GASTROENTEROLOGY
- Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
- (2014) E. R. Lutz et al. Cancer Immunology Research
- Vaccination With ENO1 DNA Prolongs Survival of Genetically Engineered Mice With Pancreatic Cancer
- (2013) Paola Cappello et al. GASTROENTEROLOGY
- Screening for Pancreatic Cancer
- (2012) Katherine E. Poruk et al. ANNALS OF SURGERY
- Annexin A2 Silencing Induces G2Arrest of Non-small Cell Lung Cancer Cells through p53-dependent and -independent Mechanisms
- (2012) Chi-Yun Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy
- (2012) Lei Zheng et al. OncoImmunology
- Overexpression of Annexin A2 Is Associated with Abnormal Ubiquitination in Breast Cancer
- (2012) Shishan Deng et al. GENOMICS PROTEOMICS & BIOINFORMATICS
- A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma
- (2011) Lutz Eric et al. ANNALS OF SURGERY
- A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
- (2011) D. T. Le et al. CLINICAL CANCER RESEARCH
- Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells
- (2011) Mercedes B. Fuertes et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Attenuated Listeria monocytogenes vaccine vectors expressing Influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers
- (2011) Paul V. Johnson et al. MICROBIOLOGY AND IMMUNOLOGY
- Tyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer
- (2011) Lei Zheng et al. PLoS One
- Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
- (2008) D. Laheru et al. CLINICAL CANCER RESEARCH
- Constitutive Activation of the PrfA Regulon Enhances the Potency of Vaccines Based on Live-Attenuated and Killed but Metabolically Active Listeria monocytogenes Strains
- (2008) P. Lauer et al. INFECTION AND IMMUNITY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started